Professor Michal Vrablik

Professor of Internal Medicine at the 1st Faculty of Medicine, Charles University in Prague, the Czech Republic

Biography

Michal Vrablik M.D., Ph.D. is currently a Professor of Internal Medicine at the 1^st Faculty of Medicine, Charles University in Prague, the Czech Republic. His main interests include preventive cardiology, clinical lipidology, CVD risk reduction strategies with special focus on very high-risk group (e.g. type 2 diabetes), and genetics of lipoprotein metabolism disorders.

He is the chairman of the Czech Atherosclerosis Society, member of board of the Czech Society of Internal Medicine and the chairman of the Czech Association of Preventive Cardiology of the Czech Society of Cardiology. He participates in the FH screening MedPed program being a leader of the project’s national center. He closely cooperates with the International Atherosclerosis Society being the chair of IAS Regional Federation for Europe since January 2019.

Dr. Vrablik has authored and co-authored more than 400 papers in peer-reviewed scientific journals. He is the sole author of three monographs and of 25 book chapters. He is also a member of editorial board as well as a reviewer for several national and international journals.

Expert content

LBPMC Publications

Safety of red yeast rice supplementation: A systematic review and meta-analysis of randomized controlled trials

Metabolic Dysfunction Associated-Steatotic Liver Disease (MASLD) and Cardiovascular Risk: Embrace All Facets of the Disease 2025-01-13
PURPOSE OF REVIEW: In recent years, the terms "metabolic associated fatty liver disease-MAFLD" and "metabolic dysfunction-associated steatotic liver disease-MASLD" were introduced to improve the encapsulation of metabolic dysregulation in this patient population, as well as to avoid the negative/stigmatizing terms "non-alcoholic" and "fatty".
Niki Katsiki
2024 Recommendations on the Optimal Use of Lipid-Lowering Therapy in Established Atherosclerotic Cardiovascular Disease and Following Acute Coronary Syndromes: A Position Paper of the International Lipid Expert Panel (ILEP) 2024-11-04
Atherosclerotic cardiovascular disease (ASCVD) and consequent acute coronary syndromes (ACS) are substantial contributors to morbidity and mortality across Europe. Fortunately, as much as two thirds of this disease's burden is modifiable, in particular by lipid-lowering therapy (LLT). Current guidelines are based on the sound premise that, with respect to low-density lipoprotein cholesterol (LDL-C), "lower is […]
Maciej Banach
Lipid and brain volumetric measures in multiple sclerosis patients: findings from a large observational study 2024-10-25
CONCLUSIONS: Our results contradict the previously described exclusively positive effect of HDL-C on brain atrophy in patients with MS. Higher LDL-C was weakly associated with higher brain atrophy but not with higher lesion burden.
Balazs Lorincz
Association of BMI, lipid-lowering medication, and age with prevalence of type 2 diabetes in adults with heterozygous familial hypercholesterolaemia: a worldwide cross-sectional study 2024-10-07
BACKGROUND: Statins are the cornerstone treatment for patients with heterozygous familial hypercholesterolaemia but research suggests it could increase the risk of type 2 diabetes in the general population. A low prevalence of type 2 diabetes was reported in some familial hypercholesterolaemia cohorts, raising the question of whether these patients are protected against type 2 diabetes. […]
European Atherosclerosis Society Familial Hypercholesterolaemia Studies Collaboration (EAS FHSC)
Development of an Emergency Department Safety Checklist through a global consensus process 2024-10-01
Emergency departments (EDs) are at high risk for medical errors. Checklist implementation programs have been associated with improved patient outcomes in other high-risk clinical settings and when used to address specific aspects of ED care. The aim of this study was to develop an ED Safety Checklist with broad applicability across different international ED settings. […]
Lucrezia Rovati
Lipid measures are associated with cognitive functioning in multiple sclerosis patients 2024-09-13
CONCLUSIONS: Our results suggest a mild negative impact of dyslipidemia on cognitive performance in patients with MS. We propose that dyslipidemia contributes, at least in part, to cognitive decline in MS patients, independent of brain atrophy.
Balázs Lőrincz
Homeostasis Model Assessment for Insulin Resistance Mediates the Positive Association of Triglycerides with Diabetes 2024-04-13
Elevated circulating triglyceride levels have been linked to an increased risk of diabetes, although the precise mechanisms remain unclear. This study aimed to investigate whether low-density lipoprotein (LDL) cholesterol, homeostatic model assessment (HOMA) for insulin resistance, and C-reactive protein (CRP) served as mediators in this association across a sample of 18,435 US adults. Mediation analysis […]
Yutang Wang
Sex Differences in Diagnosis, Treatment, and Cardiovascular Outcomes in Homozygous Familial Hypercholesterolemia 2024-02-14
CONCLUSIONS AND RELEVANCE: In this cohort study of individuals with known HoFH, MI was higher in men compared with women yet age at diagnosis and at first ASCVD event were similar. These findings suggest that early diagnosis and treatment are important in attenuating the excessive cardiovascular risk in both sexes.
Janneke W C M Mulder
Development of a hybrid point-of-care ultrasound curriculum for first year medical students in a rural medical education program: a pilot study 2024-01-03
CONCLUSIONS: Despite a lack of consensus in POCUS education, existing literature describes many curricular designs across institutions. We leveraged a combination of student initiatives, online resources, remote collaborations, local volunteers, and faculty development to bring POCUS to our institution in a rural and medically underserved region. Moreover, we demonstrate positive learning and experiential outcomes that […]
Joshua I Johnson
Familial hypercholesterolaemia in children and adolescents from 48 countries: a cross-sectional study 2023-12-15
BACKGROUND: Approximately 450 000 children are born with familial hypercholesterolaemia worldwide every year, yet only 2·1% of adults with familial hypercholesterolaemia were diagnosed before age 18 years via current diagnostic approaches, which are derived from observations in adults. We aimed to characterise children and adolescents with heterozygous familial hypercholesterolaemia (HeFH) and understand current approaches to […]
European Atherosclerosis Society Familial Hypercholesterolaemia Studies Collaboration
Genetic risk score in patients with the APOE2/E2 genotype as a predictor of familial dysbetalipoproteinemia 2023-12-03
CONCLUSIONS: We identified several SNPs that are individual additive factors influencing FD development. The use of unweighted GRS2 is a simple and clinically relevant tool that further improves the prediction of FD in APOE2/E2 homozygotes with corresponding biochemical characteristics.
Martin Satny
Lipid-lowering in diabetes: An update 2023-11-09
Atherosclerotic cardiovascular disease (ASCVD) is accelerated in people with diabetes. Dyslipidemia, hyperglycemia, oxidative stress, and inflammation play a role via a variety of mechanisms operative in the artery wall. In addition, some unique features predispose people with type 1 diabetes to accelerated atherosclerosis. Various organizations have created guidelines that provide advice regarding screening, risk assessment, […]
Alan Chait
Reporting LDL cholesterol results by clinical biochemistry laboratories in Czechia and Slovakia to improve the detection rate of familial hypercholesterolemia 2023-10-16
CONCLUSIONS: Only a small portion of laboratories from Czechia and Slovakia reported high LDL-C results with interpretative comments considering FH diagnosis in adults, the laboratories did not follow the guidelines.
Tomáš Šálek
Impact of an Institutional Clinical Pathway on Emergency Physicians' Stated Preferences in Treating Patients with Low-Risk Pulmonary Embolism 2023-10-02
CONCLUSION: Our results suggest that the implementation of an institutional clinical pathway with integration into the electronic health record was associated with a change in emergency physicians' stated preferences for managing patients with acute low-risk PE in the emergency department. Implementation of an evidence-based standard pathway was associated with increased comfort and familiarity with PE […]
Arvin Radfar Akhavan
2023 ESC Guidelines for the management of cardiovascular disease in patients with diabetes 2023-08-25
No abstract
Nikolaus Marx
The way to data: opinions and recommendations for the provision of health data for secondary use 2023-07-20
Healthcare data held by state-run organisations is a valuable intangible asset for society. Its use should be a priority for its administrators and the state. A completely paternalistic approach by administrators and the state is undesirable, however much it aims to protect the privacy rights of persons registered in databases. In line with European policies […]
Aleš Tichopád
Regional differences in physicians' behavior and factors influencing the intensity of PCSK9 inhibitor therapy with alirocumab: a subanalysis of the ODYSSEY APPRISE study 2023-07-05
CONCLUSIONS: Despite larger unmet needs and regional disparities in LDL-C targets achievement in CEE countries, more physicians in this region tend to use the higher dose of alirocumab, they are more prone to increase the dose, which is associated with a higher proportion of patients reaching LDL-C goals. The only factor that significantly influences decision […]
Maciej Banach
Cardiovascular risk in myositis patients compared with the general population 2023-06-06
CONCLUSION: Significantly higher prevalence of traditional risk factors and subclinical atherosclerosis was observed in IIM patients compared with HC.
Sabina Oreska
Low LDL-C goal attainment in patients at very high cardiovascular risk due to lacking observance of the guidelines on dyslipidaemias 2023-05-22
Dyslipidemias are defined as a wide range of abnormalities of the lipid profile. Treatment guidelines recommend aiming at lowering LDL-C. We investigated the adherence of Czech cardiologists to the dyslipidaemia treatment guidelines, especially in the management of patients with high and very high cardiovascular risk. In this retrospective cross-sectional multicentric study data from medical records […]
Michal Vrablík
Inclisiran, Low-Density Lipoprotein Cholesterol and Lipoprotein (a) 2023-04-28
Dyslipidemia treatment is of major importance in reducing the risk of atherosclerotic cardiovascular disease (ASCVD), which is still the most common cause of death worldwide. During the last decade, a novel lipid-lowering drug category has emerged, i.e., proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors. Apart from the two available anti-PCSK9 monoclonal antibodies (alirocumab and evolocumab), […]
Niki Katsiki